Soy-based beverages are well recognized for their rich nutritional contents and positive health benefits. However, there is little information regarding the composition of various commercially available soy-based beverages and uncertainty among patients regarding the utility of fermented soy products. Current study evaluates the health benefits of QCAN^® Plus—an easily available fermented soy drink. This study was performed in lean (n = 10) and obese (n = 10) subjects. The subjects were observed during pre-soy (weeks −2, −1, and 0), on-soy (weeks 1, 2, 3, and 4), and post-soy (weeks 6, 8, 10, and 12) periods. The serum samples during these visits were subjected to lipid profile analysis and multiplex assay for cytokines. The results revealed that total cholesterol and low-density lipoprotein (LDL) cholesterol levels were significantly reduced in both lean and obese individuals during on-soy (P ≤ .05). Furthermore, cytokines such as platelet-derived growth factor (PDGF) AA and AB/BB were significantly lowered on-soy compared with pre-soy (P ≤ .05) in lean subjects and PDGF AA, IL-1RA, and GMCSF were significantly reduced on-soy (P ≤ .05) in obese subjects. In addition, a qualitative and quantitative analysis of the Q-CAN Plus by a third-party laboratory confirmed its chemical and microbial safety. Our preliminary study on Q-CAN Plus ensures its safety for consumption and highlights its hypolipidemic and suppressive effect on certain cytokines. These observations and relevant studies in future might guide clinicians in future to consider Q-CAN Plus as a therapeutic nutritional supplement.

中文翻译：

---

食用发酵大豆饮料 Q-CAN Plus 可改善血清胆固醇和细胞因子。


大豆饮料因其丰富的营养成分和积极的健康益处而受到广泛认可。然而，关于各种市售豆基饮料的成分的信息很少，并且患者对发酵豆制品的效用也不确定。目前的研究评估了 QCAN ^® Plus（一种易于获取的发酵大豆饮料）的健康益处。这项研究是在瘦（ n = 10）和肥胖（ n = 10）受试者中进行的。在大豆前（第-2、-1和0周）、大豆期间（第1、2、3和4周）和大豆后（第6、8、10和12周）对受试者进行观察期间。对这些就诊期间的血清样本进行脂质谱分析和细胞因子多重测定。结果显示，在食用大豆期间，瘦人和肥胖者的总胆固醇和低密度脂蛋白 (LDL) 胆固醇水平均显着降低 ( P ≤ .05)。此外，在瘦受试者中，与食用大豆前相比，食用大豆后血小板衍生生长因子 (PDGF) AA 和 AB/BB 等细胞因子显着降低 ( P ≤ .05)，并且 PDGF AA、IL-1RA 和 GMCSF 显着降低。肥胖受试者减少大豆摄入量 ( P ≤ .05)。此外，第三方实验室对 Q-CAN Plus 进行的定性和定量分析证实了其化学和微生物安全性。我们对 Q-CAN Plus 的初步研究确保了其食用安全性，并强调了其降血脂和对某些细胞因子的抑制作用。这些观察结果和未来的相关研究可能会指导临床医生将来考虑将 Q-CAN Plus 作为治疗性营养补充剂。